Company Profiles

driven by the PitchBook Platform

Artielle ImmunoTherapeutics

Description

Provider of first-in-class platform of biologic drugs designed to treat degenerative diseases. The company's biologic drugs targets the CD74 receptor on monocytes and blocks the action of macro-phage migration inhibitory factor (MIF), enabling healthcare industry to treat neuroinflammatory and degenerative diseases including multiple sclerosis (MS), optic neuritis, methamphetamine addiction and stroke.

2004

Founded

PRIVATE

Status

1-10

Employees

Conv. Debt

Latest Deal Type

$285k

Latest Deal Amount

$15.7M

Total Amount Raised

Description

Provider of first-in-class platform of biologic drugs designed to treat degenerative diseases. The company's biologic drugs targets the CD74 receptor on monocytes and blocks the action of macro-phage migration inhibitory factor (MIF), enabling healthcare industry to treat neuroinflammatory and degenerative diseases including multiple sclerosis (MS), optic neuritis, methamphetamine addiction and stroke.

Website:

www.artielle.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

400 South El Camino Real Suite 1200 San Mateo, CA 94402United States +1 (650) 401-2000
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Artielle ImmunoTherapeutics's full profile, request a free trial.

Artielle ImmunoTherapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Artielle ImmunoTherapeutics Investors (6)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Northwest Technology VenturesVenture CapitalMinority000 0000000 0000
Pelion Venture PartnersVenture CapitalMinority000 0000000 0000
Reference Capital ManagementVenture CapitalMinority000 0000000 0000
Sanderling VenturesVenture CapitalMinority000 0000000 0000
Tenex Greenhouse VenturesVenture CapitalMinority000 0000000 0000
Northwest Technology Ventures Venture Capital
Pelion Venture Partners Venture Capital
Reference Capital Management Venture Capital
Sanderling Ventures Venture Capital
Tenex Greenhouse Ventures Venture Capital

Artielle ImmunoTherapeutics Executive Team (5)

NameTitleBoard
Seat
Contact
Info
Adolph Ferro Ph.DChief Executive Officer & President
Peter McWilliams Ph.DChairman & Acting Chief Executive Officer
Gilbert MillerDirector & Secretary
John Metcalf Ph.DDirector
Shahab FatheazamDirector
Adolph Ferro Ph.D Chief Executive Officer & President
Peter McWilliams Ph.D Chairman & Acting Chief Executive Officer
Gilbert Miller Director & Secretary
John Metcalf Ph.D Director
Shahab Fatheazam Director

Artielle ImmunoTherapeutics Board Members (1)

NameRepresentingRoleSinceContact
Info
Peter McWilliams Ph.DArtielle ImmunoTherapeuticsChairman & Acting Chief Executive Officer000 0000
Peter McWilliams Ph.D Chairman & Acting Chief Executive Officer Artielle ImmunoTherapeutics
Request full access to PitchBook